Management of Pyelonephritis

Outpatient Management

• The Infectious Diseases Society of America recommends oral fluoroquinolones as the first-line treatment for uncomplicated pyelonephritis in clinically stable patients, with ciprofloxacin 500-750 mg twice daily for 7 days or levofloxacin 750 mg once daily for 5 days 1
• Ciprofloxacin 500 mg twice daily for 7 days is highly effective, with symptom resolution in approximately 96% of patients 1
• Levofloxacin 750 mg once daily for 5 days is equally effective and FDA-approved for acute pyelonephritis 1
• Shorter fluoroquinolone regimens (5-7 days) are as effective as traditional 14-day courses 1
• If local fluoroquinolone resistance exceeds 10%, an initial intravenous dose of ceftriaxone 1 g should be given before starting oral fluoroquinolone therapy 1, 2
• Obtain urine culture before initiating antibiotics to guide therapy adjustment 2, 3
• Trimethoprim-sulfamethoxazole 160/800 mg twice daily for 14 days can be used only if the pathogen is known to be susceptible 1, 2

Inpatient Management

• Hospitalized patients require initial intravenous therapy with a fluoroquinolone, extended-spectrum cephalosporin, aminoglycoside (with or without ampicillin), or carbapenem, tailored to local resistance patterns 1, 3
• Ceftriaxone 1-2 g IV once daily is a first-line option for inpatient management 2, 3, 4
• Ciprofloxacin 400 mg IV twice daily and levofloxacin 750 mg IV once daily are also options for inpatient management 2, 3, 4
• Gentamicin 5 mg/kg IV once daily or amikacin 15 mg/kg IV once daily can be used with or without ampicillin 3
• Piperacillin/tazobactam 2.5-4.5 g IV three times daily can be used for multidrug-resistant organisms or complicated infections 2, 4
• Carbapenems should be reserved for patients with early culture results showing multidrug-resistant organisms 2, 3

Special Considerations

• Frank hematuria indicates a complicated infection requiring urgent upper urinary tract imaging to rule out obstruction, abscess, or stones 2
• Initial management of pyelonephritis with frank hematuria should follow inpatient protocols with IV antibiotics 2
• Pyelonephritis with urosepsis requires differentiation between uncomplicated and obstructive pyelonephritis immediately, as obstructive disease can rapidly progress to urosepsis 3
• Urgent decompression of the collecting system must be performed alongside antimicrobial therapy if obstruction is present 4
• If no improvement after 72 hours, obtain additional imaging and modify therapy based on culture results 3, 4

Key Recommendations

• Never use oral β-lactams as first-line therapy—they are significantly less effective than fluoroquinolones 1
• Do not use trimethoprim-sulfamethoxazole empirically without an initial parenteral dose unless susceptibility is confirmed 1
• Always obtain urine culture before starting antibiotics to allow therapy adjustment if needed 2, 3
• Do not overlook the need for imaging in patients with hematuria, persistent symptoms, or suspected complications 2, 3
• Avoid using broad-spectrum agents (carbapenems) empirically—reserve them for documented multidrug-resistant organisms to preserve their efficacy 2, 3

Piperacillin/Tazobactam for Pyelonephritis: Guideline Recommendations

First-Line Therapy

• The Infectious Diseases Society of America recommends oral fluoroquinolones (ciprofloxacin 500 mg twice daily for 7 days or levofloxacin 750 mg once daily for 5 days) as first-line therapy for outpatient uncomplicated pyelonephritis when local resistance is less than 10% 5, 6
• For inpatient empiric therapy, fluoroquinolones (IV), ceftriaxone 1-2 g once daily, or aminoglycosides are preferred initial agents 5

Piperacillin/Tazobactam Use

• The American College of Physicians suggests that piperacillin/tazobactam is not recommended as first-line empiric therapy for pyelonephritis, but is an appropriate option for hospitalized patients requiring broad-spectrum coverage, particularly when ESBL-producing organisms are suspected or confirmed 5
• Piperacillin/tazobactam demonstrates comparable efficacy to carbapenems for non-bacteremic ESBL pyelonephritis, with no difference in 30-day recurrence rates (20% vs 25%) and potentially lower risk of carbapenem-resistant organism emergence 5

Treatment Approach

• For low-risk outpatient pyelonephritis, use oral fluoroquinolone (if local resistance <10%) 5
• For high fluoroquinolone resistance (>10%), give initial IV ceftriaxone 1 g, then oral fluoroquinolone 5
• For ESBL-producing organisms susceptible to piperacillin/tazobactam, continue with prolonged infusions (4 hours) rather than switching to carbapenem 5

Empiric Management of Penicillin‑ and Sulfonamide‑Allergic Acute Pyelonephritis in Adults

First‑Line Outpatient Therapy

Adjustment for Local Fluoroquinolone Resistance

Alternative Agents When Fluoroquinolones Cannot Be Used

Diagnostic and Monitoring Steps

Duration of Therapy

Agents to Avoid in This Population

Management of Renal and Perirenal Abscesses in Pyelonephritis

Antibiotic Therapy and Drainage Strategy

• Broad‑spectrum intravenous antibiotics combined with percutaneous or surgical drainage are required for pyelonephritis with a renal or perirenal abscess; the choice of drainage method should be based on abscess size, anatomical complexity, and early clinical response. – American College of Radiology (Level of evidence not specified) 10

Small Abscesses (< 3 cm)

• Antibiotic therapy alone can achieve cure in more than 50 %–64 % of patients with small (< 3 cm) intraparenchymal renal abscesses. – American College of Radiology (Level of evidence not specified) 10

Medium‑Sized Abscesses (3–5 cm)

• Percutaneous catheter drainage (PCD) is the preferred initial approach for renal abscesses measuring 3–5 cm. – American College of Radiology (Level of evidence not specified) 10
• In abscesses that do not respond to antibiotics, PCD achieves a complete resolution rate of approximately 83 %. – American College of Radiology (Level of evidence not specified) 10
• PCD can be used as a temporizing measure before definitive surgery, with final healing rates ranging from 14 % to 32 % after subsequent operative intervention. – American College of Radiology (Level of evidence not specified) 10

Large (> 5 cm) or Perirenal Abscesses

• Perirenal abscesses almost always require an invasive intervention (percutaneous or surgical). – American College of Radiology (Level of evidence not specified) 10

Indications for Urgent Nephrectomy

• Urgent nephrectomy should be considered when conservative management (antibiotics ± PCD) fails after 48–72 hours. – American College of Radiology (Level of evidence not specified) 10